AB68-SSA1,2977
18Section
2977. 632.746 (1) (a) of the statutes is renumbered 632.746 (1) and
19amended to read:
AB68-SSA1,1348,220
632.746
(1) Subject to subs. (2) and (3), an An insurer that offers a group health
21benefit plan may
, with respect to a participant or beneficiary under the plan, not 22impose a preexisting condition exclusion
only if the exclusion relates to a condition,
23whether physical or mental, regardless of the cause of the condition, for which
24medical advice, diagnosis, care or treatment was recommended or received within
1the 6-month period ending on the participant's or beneficiary's enrollment date
2under the plan on a participant or beneficiary under the plan.
AB68-SSA1,2978
3Section
2978. 632.746 (1) (b) of the statutes is repealed.
AB68-SSA1,2979
4Section
2979. 632.746 (2) (a) of the statutes is amended to read:
AB68-SSA1,1348,85
632.746
(2) (a) An insurer offering a group health benefit plan may not
treat 6impose a preexisting condition exclusion based on genetic information
as a
7preexisting condition under sub. (1) without a diagnosis of a condition related to the
8information.
AB68-SSA1,2980
9Section
2980. 632.746 (2) (c), (d) and (e) of the statutes are repealed.
AB68-SSA1,2981
10Section
2981. 632.746 (3) (a) of the statutes is repealed.
AB68-SSA1,2982
11Section 2982
. 632.746 (3) (d) 1. of the statutes is renumbered 632.746 (3) (d).
AB68-SSA1,2983
12Section 2983
. 632.746 (3) (d) 2. and 3. of the statutes are repealed.
AB68-SSA1,2984
13Section 2984
. 632.746 (5) of the statutes is repealed.
AB68-SSA1,2985
14Section
2985. 632.746 (8) (a) (intro.) of the statutes is amended to read:
AB68-SSA1,1348,1815
632.746
(8) (a) (intro.) A health maintenance organization that offers a group
16health benefit plan
and that does not impose any preexisting condition exclusion
17under sub. (1) with respect to a particular coverage option may impose an affiliation
18period for that coverage option, but only if all of the following apply:
AB68-SSA1,2986
19Section 2986
. 632.748 (2) of the statutes is amended to read:
AB68-SSA1,1349,220
632.748
(2) An insurer offering a group health benefit plan may not require any
21individual, as a condition of enrollment or continued enrollment under the plan, to
22pay, on the basis of any health status-related factor with respect to the individual
23or a dependent of the individual, a premium or contribution
or a deductible,
24copayment, or coinsurance amount that is greater than the premium or contribution
1or deductible, copayment, or coinsurance amount respectively for a similarly
2situated individual enrolled under the plan.
AB68-SSA1,2987
3Section
2987. 632.7495 (4) (b) of the statutes is amended to read:
AB68-SSA1,1349,44
632.7495
(4) (b) The coverage has a term of not more than
12 3 months.
AB68-SSA1,2988
5Section
2988. 632.7495 (4) (c) of the statutes is amended to read:
AB68-SSA1,1349,106
632.7495
(4) (c) The coverage term aggregated with all consecutive periods of
7the insurer's coverage of the insured by individual health benefit plan coverage not
8required to be renewed under this subsection does not exceed
18 6 months. For
9purposes of this paragraph, coverage periods are consecutive if there are no more
10than 63 days between the coverage periods.
AB68-SSA1,2989
11Section 2989
. 632.7496 of the statutes is created to read:
AB68-SSA1,1349,14
12632.7496 Coverage requirements for short-term plans. (1) Definition. 13In this section, “short-term, limited duration plan” means an individual health
14benefit plan described in s. 632.7495 (4) that an insurer is not required to renew.
AB68-SSA1,1349,17
15(2) Guaranteed issue. Every short-term, limited duration plan shall accept
16every individual in this state who applies for coverage whether or not any individual
17has a preexisting condition.
AB68-SSA1,1349,22
18(3) Prohibiting discrimination based on health status. (a) A short-term,
19limited duration plan may not establish rules for the eligibility of any individual to
20enroll, or for the continued eligibility of any individual to remain enrolled, under the
21plan based on any of the following health status-related factors in relation to the
22individual or a dependent of the individual:
AB68-SSA1,1349,2323
1. Health status.
AB68-SSA1,1349,2424
2. Medical condition, including both physical and mental illnesses.
AB68-SSA1,1349,2525
3. Claims experience.
AB68-SSA1,1350,1
14. Receipt of health care.
AB68-SSA1,1350,22
5. Medical history.
AB68-SSA1,1350,33
6. Genetic information.
AB68-SSA1,1350,54
7. Evidence of insurability, including conditions arising out of acts of domestic
5violence.
AB68-SSA1,1350,66
8. Disability.
AB68-SSA1,1350,137
(b) A short-term, limited duration plan may not require any individual, as a
8condition of enrollment or continued enrollment under the plan, to pay, on the basis
9of any health status-related factor under par. (a) with respect to the individual or a
10dependent of the individual, a premium or contribution or a deductible, copayment,
11or coinsurance amount that is greater than the premium or contribution or
12deductible, copayment, or coinsurance amount respectively for a similarly situated
13individual enrolled under the plan.
AB68-SSA1,1350,15
14(4) Premium rate variation. A short-term, limited duration plan may vary
15premium rates for a specific plan based only on the following considerations:
AB68-SSA1,1350,1616
(a) Whether the policy or plan covers an individual or a family.
AB68-SSA1,1350,1717
(b) Rating area in the state, as established by the commissioner.
AB68-SSA1,1350,2018
(c) Age, except that the rate may not vary by more than 3 to 1 for adults over
19the age groups and the age bands shall be consistent with recommendations of the
20National Association of Insurance Commissioners.
AB68-SSA1,1350,2121
(d) Tobacco use, except that the rate may not vary by more than 1.5 to 1.
AB68-SSA1,1350,23
22(5) Annual and lifetime limits. A short-term, limited duration plan may not
23establish any of the following:
AB68-SSA1,1350,2524
(a) Lifetime limits on the dollar value of benefits for an enrollee or a dependent
25of an enrollee under the plan.
AB68-SSA1,1351,2
1(b) Limits on the dollar value of benefits for an enrollee or a dependent of an
2enrollee under the plan for the initial or cumulative duration of the plan.
AB68-SSA1,2990
3Section
2990. 632.76 (2) (a) and (ac) 1. and 2. of the statutes are amended to
4read:
AB68-SSA1,1351,125
632.76
(2) (a) No claim for loss incurred or disability commencing after 2 years
6from the date of issue of the policy may be reduced or denied on the ground that a
7disease or physical condition existed prior to the effective date of coverage, unless the
8condition was excluded from coverage by name or specific description by a provision
9effective on the date of loss. This paragraph does not apply to a group health benefit
10plan, as defined in s. 632.745 (9), which is subject to s. 632.746
, a disability insurance
11policy, as defined in s. 632.895 (1) (a), or a self-insured health plan, as defined in s.
12632.85 (1) (c).
AB68-SSA1,1351,1813
(ac) 1.
Notwithstanding par. (a), no No claim or loss incurred or disability
14commencing
after 12 months from the date of issue of
under an individual disability
15insurance policy, as defined in s. 632.895 (1) (a), may be reduced or denied on the
16ground that a disease or physical condition existed prior to the effective date of
17coverage
, unless the condition was excluded from coverage by name or specific
18description by a provision effective on the date of the loss.
AB68-SSA1,1351,2519
2.
Except as provided in subd. 3., an An individual disability insurance policy,
20as defined in s. 632.895 (1) (a), other than a short-term policy subject to s. 632.7495
21(4) and (5), may not define a preexisting condition more restrictively than a condition
22that was present before the date of enrollment for the coverage, whether physical or
23mental, regardless of the cause of the condition,
for which and regardless of whether 24medical advice, diagnosis, care, or treatment was recommended or received
within
2512 months before the effective date of coverage.
AB68-SSA1,2991
1Section
2991. 632.76 (2) (ac) 3. (intro.) of the statutes is amended to read:
AB68-SSA1,1352,42
632.76
(2) (ac) 3. (intro.) Except as the commissioner provides by rule under
3s. 632.7495 (5), all of the following apply to an individual disability insurance policy
4that is a short-term
, limited duration policy subject to s. 632.7495 (4) and (5):
AB68-SSA1,2992
5Section
2992. 632.76 (2) (ac) 3. b. of the statutes is amended to read:
AB68-SSA1,1352,116
632.76
(2) (ac) 3. b. The policy
shall reduce the length of time during which a 7may not impose any preexisting condition exclusion
may be imposed by the
8aggregate of the insured's consecutive periods of coverage under the insurer's
9individual disability insurance policies that are short-term policies subject to s.
10632.7495 (4) and (5). For purposes of this subd. 3. b., coverage periods are consecutive
11if there are no more than 63 days between the coverage periods.
AB68-SSA1,2993
12Section
2993. 632.795 (4) (a) of the statutes is amended to read:
AB68-SSA1,1352,2413
632.795
(4) (a) An insurer subject to sub. (2) shall provide coverage under the
14same policy form and for the same premium as it originally offered in the most recent
15enrollment period, subject only to the medical underwriting used in that enrollment
16period. Unless otherwise prescribed by rule, the insurer may apply deductibles,
17preexisting condition limitations, waiting periods
, or other limits only to the extent
18that they would have been applicable had coverage been extended at the time of the
19most recent enrollment period and with credit for the satisfaction or partial
20satisfaction of similar provisions under the liquidated insurer's policy or plan. The
21insurer may exclude coverage of claims that are payable by a solvent insurer under
22insolvency coverage required by the commissioner or by the insurance regulator of
23another jurisdiction. Coverage shall be effective on the date that the liquidated
24insurer's coverage terminates.
AB68-SSA1,2994
25Section
2994. 632.796 of the statutes is created to read:
AB68-SSA1,1353,2
1632.796 Drug cost report.
(1) Definition. In this section, “disability
2insurance policy” has the meaning given in s. 632.895 (1) (a).
AB68-SSA1,1353,8
3(2) Report required. Annually, at the time the insurer files its rate request
4with the commissioner, each insurer that offers a disability insurance policy that
5covers prescription drugs shall submit to the commissioner a report that identifies
6the 25 prescription drugs that are the highest cost to the insurer and the 25
7prescription drugs that have the highest cost increases over the 12 months before the
8submission of the report.
AB68-SSA1,2995
9Section
2995. 632.862 of the statutes is created to read:
AB68-SSA1,1353,11
10632.862 Application of prescription drug payments. (1) Definitions. In
11this section:
AB68-SSA1,1353,1212
(a) “Brand name” has the meaning given in s. 450.12 (1) (a).
AB68-SSA1,1353,1313
(b) “Brand name drug” means any of the following:
AB68-SSA1,1353,1514
1. A prescription drug that contains a brand name and that has no generic
15equivalent.
AB68-SSA1,1353,1916
2. A prescription drug that contains a brand name and has a generic equivalent
17but for which the enrollee has received prior authorization from the insurer offering
18the disability insurance policy or the self-insured health plan or authorization from
19a physician to obtain the prescription drug under the policy or plan.
AB68-SSA1,1353,2020
(c) “Disability insurance policy” has the meaning given in s. 632.895 (1) (a).
AB68-SSA1,1353,2121
(d) “Prescription drug” has the meaning given in s. 450.01 (20)
AB68-SSA1,1353,2222
(e) “Self-insured health plan” has the meaning given in s. 632.85 (1) (c).
AB68-SSA1,1354,3
23(2) Application of discounts. A disability insurance policy that offers a
24prescription drug benefit or a self-insured health plan shall apply to any calculation
25of an out-of-pocket maximum and to any deductible of the policy or plan for an
1enrollee the amount that any discount provided by the manufacturer of a brand
2name drug reduces the cost sharing amount charged to an enrollee for that brand
3name drug.
AB68-SSA1,2996
4Section
2996. 632.863 of the statutes is created to read:
AB68-SSA1,1354,5
5632.863 Pharmaceutical representatives. (1) Definitions. In this section:
AB68-SSA1,1354,86
(a) “Health care professional” means a physician or other health care
7practitioner who is licensed to provide health care services or to prescribe
8pharmaceutical or biologic products.
AB68-SSA1,1354,109
(b) “Pharmaceutical” means a medication that may legally be dispensed only
10with a valid prescription from a health care professional.
AB68-SSA1,1354,1311
(c) “Pharmaceutical representative” means an individual who markets or
12promotes pharmaceuticals to health care professionals on behalf of a pharmaceutical
13manufacturer for compensation.
AB68-SSA1,1354,1714
(d) “Wholesale acquisition cost” means the most recently reported
15manufacturer list or catalog price for a brand-name drug or generic drug available
16to wholesalers or direct purchasers in the United States, before application of
17discounts, rebates, or reductions in price.
AB68-SSA1,1354,23
18(2) Licensure. (a) No individual may act as a pharmaceutical representative
19in this state without obtaining a pharmaceutical representative license. In order to
20obtain a license, an individual shall apply to the commissioner, on a form prescribed
21by the commissioner. A license issued under this paragraph shall be renewed on an
22annual basis. The application to obtain or renew a license shall include all of the
23following information:
AB68-SSA1,1354,2524
1. The applicant's full name, residence address and telephone number, and
25business address and telephone number.
AB68-SSA1,1355,1
12. A description of the type of work in which the applicant will engage.
AB68-SSA1,1355,22
3. The fee under s. 601.31 (1) (nv).
AB68-SSA1,1355,43
4. An attestation that the applicant meets the professional education
4requirements under sub. (3).
AB68-SSA1,1355,55
5. Proof that the applicant has paid any assessed penalties and fees.
AB68-SSA1,1355,66
6. Any other information required by the commissioner.
AB68-SSA1,1355,117
(b) The pharmaceutical representative shall report, in writing, to the
8commissioner any change to the information submitted on the application under par.
9(a) or any material change to the pharmaceutical representative's business
10operations or to any information provided under this section. The report shall be
11made no later than 4 business days after the change or material change occurs.
AB68-SSA1,1355,1312
(c) A pharmaceutical representative shall display his or her license during each
13visit with a health care professional.
AB68-SSA1,1355,18
14(3) Professional education requirements. (a) In order to become initially
15licensed under sub. (2) (a), a pharmaceutical representative shall complete a
16professional education course as determined by the commissioner. A pharmaceutical
17representative shall, upon request, provide the commissioner with proof of the
18coursework's completion.
AB68-SSA1,1355,2219
(b) In order to renew a license under sub. (2) (a), a pharmaceutical
20representative shall complete a minimum of 5 hours of continuing professional
21education courses. A pharmaceutical representative shall, upon request, provide the
22commissioner with proof of the coursework's completion.
AB68-SSA1,1356,223
(c) The professional education coursework required under pars. (a) and (b) shall
24include training in ethical standards, whistleblower protections, laws and rules
1applicable to pharmaceutical marketing, and other areas that the commissioner may
2identify by rule.
AB68-SSA1,1356,43
(d) The commissioner shall regularly designate courses that fulfill the
4requirements under this subsection and publish a list of the designated courses.
AB68-SSA1,1356,95
(e) The professional education coursework required under this subsection may
6not be provided by the employer of a pharmaceutical representative or be funded, in
7any way, by the pharmaceutical industry or a 3rd party funded by the
8pharmaceutical industry. A provider of a course designated under par. (d) shall
9disclose any conflict of interest.
AB68-SSA1,1356,13
10(4) Disclosure to commissioner. (a) No later than June 1 of each year, a
11pharmaceutical representative shall provide to the commissioner, in the manner
12prescribed by the commissioner, all of the following information from the previous
13calendar year:
AB68-SSA1,1356,1614
1. The total number of times the pharmaceutical representative contacted
15health care professionals in this state and the specialties of the health care
16professionals contacted.
AB68-SSA1,1356,2017
2. For each contact with a health care professional in this state, the location and
18duration of the contact, the pharmaceuticals for which the pharmaceutical
19representative provides information, and the value of any item, including a product
20sample, compensation, material, or gift, provided to the health care professional.
AB68-SSA1,1356,2321
(b) The commissioner shall publish the information provided under par. (a) on
22the commissioner's Internet site in a manner in which individual health care
23professionals are not identifiable by name or other identifiers.
AB68-SSA1,1357,4
24(5) Disclosure to health care professionals. During each contact with a
25health care professional, a pharmaceutical representative shall disclose the
1wholesale acquisition cost of any pharmaceutical for which the pharmaceutical
2representative provides information and the names of at least 3 generic prescription
3drugs from the same therapeutic class, or if 3 are not available, as many as are
4available for prescriptive use.
AB68-SSA1,1357,9
5(6) Ethical standards. The commissioner shall promulgate a rule that
6contains ethical standards for pharmaceutical representatives and shall publish the
7ethical standards on the commissioner's Internet site. In addition to the ethical
8standards contained in the rule, a pharmaceutical representative may not do any of
9the following:
AB68-SSA1,1357,1210
(a) Engage in deceptive or misleading marketing of a pharmaceutical,
11including the knowing concealment, suppression, omission, misleading
12representation, or misstatement of a material fact.